Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05989269 · ClinicalTrials.gov registry record · NA

Diagnostic Stewardship for Ventilator Associated Pneumonia

A NA study, sponsored by University of Maryland, Baltimore.

Completed
Registry status
NA
Development phase
161
Enrollment target

NCT05989269: Completed NA study, sponsored by University of Maryland, Baltimore.

NCT05989269 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 161 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05989269, a NA study, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
NA
Development phase
161 participants
Enrollment target

Study Summary

The goal of this pragmatic cluster-randomized crossover trial is to test if less unnecessary antibiotics are prescribed when the lab reports respiratory culture test results in a specific way for patients who have respiratory cultures obtained, but do not meet clinical criteria for ventilator associated pneumonia (VAP). The main question it aims to answer is: Does a modified culture reporting intervention reduce unnecessary antibiotics for ventilated patients in the intensive care unit (ICU)? Researchers will compare antibiotic use outcomes between eligible patients whose test results are communicated using the modified reporting and those with standard reporting of results.

Primary Outcome

The primary efficacy outcome is change in proportion of unnecessary antibiotic therapy for presumed VAP in the intervention (modified reporting) period compared to control (standard reporting) period. Antibiotic use for VAP relative to the index respiratory culture will be classified as follows: 1. Not on empiric antibiotic(s), new antibiotic started based on index respiratory culture result 2. Not on empiric antibiotic(s), no new antibiotics initiated based on culture result 3. On empiric ant

Interventions

  • OTHER Modified lab reporting

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2023-08-21
Est. Completion 2025-03-30
Phase NA
University of Maryland, Baltimore

560 total trials

What the finished NCT05989269 record still lists

NCT05989269 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 1 intervention - of which Modified lab reporting is the first listed.

NCT05989269 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05989269 about?

NCT05989269 is a clinical study titled "Diagnostic Stewardship for Ventilator Associated Pneumonia". The goal of this pragmatic cluster-randomized crossover trial is to test if less unnecessary antibiotics are prescribed when the lab reports respiratory culture test results in a specific way for patients who have respiratory cultures obtained, but do not meet clinical criteria for ventilator associ...

What is the current status of trial NCT05989269?

This trial is currently completed. It is a NA study. The enrollment target is 161 participants. The study started on 2023-08-21. Estimated completion is 2025-03-30.

What interventions are being tested in trial NCT05989269?

The interventions under investigation include: Modified lab reporting (OTHER).

Who is sponsoring clinical trial NCT05989269?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05989269's enrollment target sits among peer trials

161 628th of 2000 higher than 1,373 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06391034 · 161 participants · Phase 2

    Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

  • NCT06546670 · 161 participants · Phase 1

    A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

  • NCT06616766 · 161 participants · Phase 1

    A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

  • NCT06752356 · 161 participants · Phase 3

    A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05989269, the US trial registry maintained by the National Library of Medicine. NCT05989269 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.